Trials / Completed
CompletedNCT04515888
Evaluation of the Prevalence of Pelvic Static Disorders in Women With Localized Breast Cancer
Evaluation of the Prevalence of Pelvic Static Disorders in Women Treated for Localized Breast Cancer During Adjuvant Hormone Therapy.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 246 (actual)
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle · Academic / Other
- Sex
- Female
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
In this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients
Detailed description
Breast cancer is the most common cancer in women. Its incidence increases with 58,459 new cases in France in 2018, however its mortality decreases with a survival rate of 87% at 5 years. Therapeutic options are surgery, radiotherapy, chemotherapy and hormone therapy. Hormone therapy is one of the major treatments for hormone-sensitive tumors with a prescription made in around 70% of breast cancer cases. These different hormone therapies cause a hormonal imbalance with in particular an important anti-estrogenic action. Hormonal deprivation and menopause can be responsible for the occurrence of pelvic statics disorder.\[5-9\] Pelvic static disorder (PTS) is a common problem for women, which can occur at any age. These disorders include urinary incontinence, stress or urgency, anal incontinence, genital prolapse. Hypothesis's investigator is that hormone therapy may be responsible for PTS. In this study, investigator propose to assess the prevalence of pelvic static disorders in women undergoing adjuvant hormone therapy for localized breast cancer and to assess the overall quality of life in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | PFDI-20 / PFIQ-7 questionnaires | PFDI-20 / PFIQ-7 questionnaires (one shot) |
Timeline
- Start date
- 2020-09-18
- Primary completion
- 2021-02-12
- Completion
- 2021-07-06
- First posted
- 2020-08-17
- Last updated
- 2021-11-04
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04515888. Inclusion in this directory is not an endorsement.